Journal of Hepatology
Volume 52, Issue 3 , Pages 362-369 , March 2010

The αvβ6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma

  • E. Patsenker

      Affiliations

    • Institute of Clinical Pharmacology and Visceral Research, University of Bern, Murtenstrasse 35, 3010 Bern, Switzerland
    • ,
  • L. Wilkens

      Affiliations

    • Institute of Pathology, University of Bern, Switzerland
    • ,
  • V. Banz

      Affiliations

    • Department of Visceral Surgery and Medicine, Inselspital Bern, Switzerland
    • ,
  • C.H. Österreicher

      Affiliations

    • Department of Medicine, University of California, San Diego, CA, USA
    • ,
  • R. Weimann

      Affiliations

    • Institute of Pathology, University of Bern, Switzerland
    • ,
  • S. Eisele

      Affiliations

    • Institute of Clinical Pharmacology and Visceral Research, University of Bern, Murtenstrasse 35, 3010 Bern, Switzerland
    • ,
  • A. Keogh

      Affiliations

    • Department of Visceral Surgery and Medicine, Inselspital Bern, Switzerland
    • ,
  • D. Stroka

      Affiliations

    • Department of Visceral Surgery and Medicine, Inselspital Bern, Switzerland
    • ,
  • A. Zimmermann

      Affiliations

    • Institute of Pathology, University of Bern, Switzerland
    • ,
  • F. Stickel

      Affiliations

    • Institute of Clinical Pharmacology and Visceral Research, University of Bern, Murtenstrasse 35, 3010 Bern, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 31 6328728; fax: +41 31 632 49 97.

Received 2 April 2009 ,Revised 21 August 2009 ,Accepted 17 September 2009.

References 

  1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–1314
  2. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3:33–42
  3. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006;45:856–867
  4. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(Suppl. 6):VI1–VI9
  5. Brumm C, Schulze C, Charels K, Morohoshi T, Kloppel G. The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours. Histopathology. 1989;14:503–513
  6. Ganjei P, Nadji M, Albores-Saavedra J, Morales AR. Histologic markers in primary and metastatic tumors of the liver. Cancer. 1988;62:1994–1998
  7. Jovanovic R, Jagirdar J, Thung SN, Paronetto F. Blood-group-related antigen Lewis(x) and Lewis(y) in the differential diagnosis of cholangiocarcinoma and hepatocellular carcinoma. Arch Pathol Lab Med. 1989;113:139–142
  8. Nakajima T, Kondo Y. Well-differentiated cholangiocarcinoma: diagnostic significance of morphologic and immunohistochemical parameters. Am J Surg Pathol. 1989;13:569–573
  9. Kakar S, Gown AM, Goodman ZD, Ferrell LD. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med. 2007;131:1648–1654
  10. Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 2000;24:870–876
  11. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687
  12. Volpes R, van den Oord JJ, Desmet VJ. Integrins as differential cell lineage markers of primary liver tumors. Am J Pathol. 1993;142:1483–1492
  13. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med. 1999;222:124–138
  14. Van Waes C. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Head Neck. 1995;17:140–147
  15. Eble JA, Haier J. Integrins in cancer treatment. Curr Cancer Drug Targets. 2006;6:89–105
  16. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol. 1992;23:1159–1166
  17. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology. 2008;135:660–670
  18. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol. 2008;48:453–464
  19. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995;108(Pt 6):2241–2251
  20. Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem. 1993;41:1521–1527
  21. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–981
  22. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H, et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology. 2004;45:226–236
  23. Xue H, Atakilit A, Zhu W, Li X, Ramos DM, Pytela R. Role of the alpha(v)beta6 integrin in human oral squamous cell carcinoma growth in vivo and in vitro. Biochem Biophys Res Commun. 2001;288:610–618
  24. Regezi JA, Ramos DM, Pytela R, Dekker NP, Jordan RC. Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol. 2002;38:332–336
  25. Kawashima A, Tsugawa S, Boku A, Kobayashi M, Minamoto T, Nakanishi I, et al. Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis. Pathol Res Pract. 2003;199:57–64
  26. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995;177:61–71
  27. Maruyama M, Kobayashi N, Westerman KA, Sakaguchi M, Allain JE, Totsugawa T, et al. Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation. 2004;77:446–451
  28. Joplin R. Isolation and culture of biliary epithelial cells. Gut. 1994;35:875–878
  29. Hernandez BY, Frierson HF, Moskaluk CA, Li YJ, Clegg L, Cote TR, et al. CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol. 2005;36:275–281
  30. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)−/− mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol. 2005;43:1045–1054
  31. Patsenker E, Popov Y, Wiesner M, Goodman SL, Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol. 2007;46:878–887
  32. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996;149:1167–1175
  33. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol. 1989;134:1347–1363
  34. Hakkinen L, Koivisto L, Gardner H, Saarialho-Kere U, Carroll JM, Lakso M, et al. Increased expression of beta6-integrin in skin leads to spontaneous development of chronic wounds. Am J Pathol. 2004;164:229–242
  35. Wang B, Dolinski BM, Kikuchi N, Leone DR, Peters MG, Weinreb PH, et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology. 2007;46:1404–1412
  36. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33:283–287
  37. Ng IO, Shek TW, Nicholls J, Ma LT. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol. 1998;13:34–40
  38. Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem. 2002;50:1371–1380
  39. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 2005;115:339–347
  40. Smythe WR, LeBel E, Bavaria JE, Kaiser LR, Albelda SM. Integrin expression in non-small cell carcinoma of the lung. Cancer Metastasis Rev. 1995;14:229–239
  41. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest. 2008;88:112–123

PII: S0168-8278(09)00807-1

doi: 10.1016/j.jhep.2009.12.006

Journal of Hepatology
Volume 52, Issue 3 , Pages 362-369 , March 2010

Article Tools

* Image Usage & Resolution